CytoGenomics to Support Affy, GenePix Data
CytoGenomics’ SilicoCyte 1.4 microarray platform will support the import of data from Affymetrix’s MAS Suite 5.0 and Axon’s GenePix Pro, CytoGenomics announced.
The SilicoCyte update has additional normalization features and allows “easy” import of GAL files, the company said. The data also can be stored in SilicoCyte’s data warehouse for mining and analysis.
NovusGene, Mitsui to Distribute DNA Chip Products
DNA Chip Research said this week that it has formed a DNA chip product distribution pact with Mitsui and NovusGene. Under the terms of the deal, NovusGene will market DNA Chip Research’s proprietary products including the AceGene series and also accept orders for DNA analysis services. NovusGene is a joint venture between Mitsui, Mitsui Knowledge, and Olympus Optical.
The deal also includes the use of Mitsui’s distribution channels to raw material manufacturers, pharmaceutical firms, and genetic analysis companies. The partners expect to achieve annual sales of ¥100 million ($910,000) in the future.
University of Iowa licenses Partek Pro
The University of Iowa has purchased site licenses for Partek Pro software for use in statistical and visual analysis of microarray data, the St. Louis-based company said last week.
Financial details of the transaction were not disclosed.
AIST to Use IBM’s BlueGene for Protein Research
IBM has announced that Japanese research laboratory Advanced Industrial Science and Technology will use the IBM BlueGene/L supercomputer to predict 3D protein structures.
The BlueGene/L system will be installed in February 2005 at the Computational Biology Research Center at Tokyo-based AIST. The system will have a peak processing speed of 22.8 trillion calculations per second.
IBM said that it was discussing possible areas for joint research with AIST using application software that IBM has specifically designed for researching protein simulations on BlueGene/L.
AIST joins the Argonne National Laboratory in the US and the Dutch astronomical organization Astron, both of which will start using the BlueGene/L supercomputer next year.
CombiMatrix, Intel to Collaborate
CombiMatrix has entered into an agreement with Intel to work together on the feasibility of various projects utilizing CombiMatrix’s core technology.
The firms would not disclose the terms of the alliance and would not provide specific information about the projects they are working on. A CombiMatrix spokesman told BioArray News sister publication GenomeWeb News that the collaboration would “leverage our core technology” and would be applied to internal projects at Intel.
Serologicals to Acquire Upstate for $205 Million
Serologicals has entered into a definitive agreement to acquire Upstate Group for a combination of cash and stock worth $205 million.
Atlanta-based Serologicals said that it will issue up to 5 million shares of its common stock, and the balance of the price will be paid in cash.
Privately held Upstate employs 260 people worldwide and recorded revenues of $44.4 million for fiscal year 2003. The firm is based in Charlottesville, Va., and has manufacturing facilities in Lake Placid, N.Y., and Dundee, Scotland.
Upstate sells cell-signaling research reagents to academic, biotech, and pharmaceutical investigators. Serologicals expects the deal will provide the company with a significant presence in the preclinical drug screening and target validation market, with a focus on kinase screening and protein interaction. The firm also said that it expects the Upstate and Chemicon subsidiaries to launch approximately 1,500 new research products per year.
Serologicals, which anticipates closing the acquisition in the fourth quarter of this year, said the deal will add roughly $80 million to its revenues and between $.03 and $.05 to its diluted earnings per share in fiscal 2005. The acquisition was approved by Serologicals’ board of directors and by holders of approximately 90 percent of the shares of voting stock of Upstate.
JPMorgan Chase will finance the cash portion of the purchase under a new credit facility for Serologicals.
TriCore to use Third Wave Reagents
Third Wave Technologies announced that TriCore Reference Laboratories has adopted the firm’s Invader hepatitis C virus genotyping reagents for developing assays to identify all six genotypes of HCV.
According to Madison, Wis.-based Third Wave, TriCore selected the Third Wave reagents after a head-to-head comparison with competing products. TriCore operates reference labs serving clients in the Southwestern US.
Genospectra Raises $16.4 Million in Private Financing
Genospectra has raised $16.4 million in a Series C financing round, the company announced this week.
Fremont, Calif.-based Geospectra plans to use the funding to develop cell-based assays and a quantitative cell-based method for gene expression profiling.
Batelle Ventures led the financing round. New investors were Agilent Ventures, 5AM Ventures, Aravis Ventures, Allen & Co., and private investors. They were joined by existing investors Alex Zaffaroni, Frazier Healthcare Ventures, HBM Bioventures, Novartis Bioventures, Bio*One Capital, Bay City Capital, and Affymetrix.
National Academies’ Panel Gives Nod to Continued Open Access to Pathogen Genomic Data
A blue-ribbon panel has released a report that recommends no changes in policies that give unrestricted public access to genomic data on microbial pathogens, but said an advisory board should be created to review security implications as genome research continues.
The committee, organized by the National Academies’ National Research Council and charged with reporting on how biological scientists view policies governing access, said that open access to such data is essential.
Completed genomic sequences of more than 100 microbial pathogens — including smallpox, anthrax, and Ebola hemorrhagic fever — are publicly available in Internet-accessible databases, and any genomic data produced using US federal funding are required to be made public.
Perlegen Awarded NIH Grant for Alzheimer’s Genome Study
Perlegen Sciences said that it has been awarded a grant from the National Institute on Aging to conduct a whole-genome association study in order to find the genetic determinants of Alzheimer’s disease.
According to the company, the study will involve the use of an oligonucleotide array-based genotyping platform to genotype over 1.5 million SNPs across the genome in late-onset Alzheimer’s disease patients, as well as controls.